Evaluation of the significance of circulating insulin-like growth factor-1 and C-reactive protein in patients with chronic obstructive pulmonary disease

Journal of International Medical Research

Volumn 40, Issue 3, 2012, Pages 1025-1035

  Ye, M ^a   Yu, H ^a   Yu, W ^a   Zhang, G ^a   Xiao, L ^a   Zheng, X ^a   Wu, Jiewen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease (COPD); COPD exacerbation; Insulin Like Growth Factor 1; Puscle wasting

Indexed keywords

ALBUMIN; BUDESONIDE; C REACTIVE PROTEIN; FLUTICASONE; SALBUTAMOL SULFATE; SOMATOMEDIN C;

AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MUSCLE ATROPHY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 84863105804     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000321     Document Type: Article

References (33)

1. Rabe KF, Hurd S, Anzueto A, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
2. Laghi F, Adiguzel N, Tobin MJ: Endocrinological derangements in COPD. Eur Respir J 2009; 34: 975-996.
3. Sergi G, Coin A, Marin S, et al: Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir Med 2006; 100: 1918-1924.
4. Koehler F, Doehner W, Hoernig S, et al: Anorexia in chronic obstructive pulmonary disease-association to cachexia and hormonal derangement. Int J Cardiol 2007; 119: 83-89.
5. Kythreotis P, Kokkini A, Avgeropoulou S, et al: Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 2009; 9: 11.
6. Coşkun F, Ege E, Uzaslan E, et al: Evaluation of thyroid hormone levels and somatomedin-C (IGF-1) in patients with chronic obstructive pulmonary disease (COPD) and relation with the severity of the disease. Tuberk Toraks 2009; 57: 369-375.
7. de Torres JP, Pinto-Plata V, Casanova C, et al: Creactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133: 1336-1343.
8. Cano NJ, Pichard C, Roth H, et al: C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126: 540-546.
9. Karadag F, Kirdar S, Karul AB, et al: The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008; 19: 104-108.
10. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.
11. Pinto-Plata VM, Müllerova H, Toso JF, et al: Creactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
12. World Health Organization: Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452.
13. Spruit MA, Gosselink R, Troosters T, et al: Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-1. Thorax 2003; 58: 752-756.
14. Mohan S, Baylink DJ: IGF-binding proteins are multifunctional and act via IGF-dependent and-independent mechanisms. J Endocrinol 2002; 175: 19-31.
15. Domené HM, Bengolea SV, Jasper HG, et al: Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest 2005; 28(5 suppl): 43-46.
16. Fernández-Celemín L, Thissen JP: Interleukin-6 stimulates hepatic insulin-like growth factor binding protein-4 messenger ribonucleic acid and protein. Endocrinology 2001; 142: 241-248.
17. Broekhuizen R, Wouters EF, Creutzberg EC, et al: Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
18. Sassoon CS, Zhu E, Pham HT, et al: Acute effects of high-dose methylprednisolone on diaphragm muscle function. Muscle Nerve 2008; 38: 1161-1172.
19. Sharafkhaneh A, Mattewal AS, Abraham VM, et al: Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis 2010; 5: 357-366.
20. Sin DD, Man SF, Marciniuk DD, et al: The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-1214.
21. Tattersfield AE, Harrison TW, Hubbard RB, et al: Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1: 171-175.
22. Schuetz P, Christ-Crain M, Schild U, et al: Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med 2008; 8: 1.
23. Shin SY, Lee JR, Noh GW, et al: Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulinlike growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status. J Korean Med Sci 2008; 23: 104-110.
24. Vermeeren MA, Creutzberg EC, Schols AM, et al: Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006; 100: 1349-1355.
25. Crul T, Spruit MA, Gayan-Ramirez G, et al: Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest 2007; 37: 897-904.
26. Man SF, Connett JE, Anthonisen NR, et al: Creactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849-853.
27. Piehl-Aulin K, Jones I, Lindvall B, et al: Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 2009; 78: 191-196.
28. Hurst JR, Donaldson GC, Perera WR, et al: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867-874.
29. Sin DD, Lacy P, York E, et al: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765.
30. Maltais F: Skeletal muscles in chronic airflow obstruction: why bother? Am J Respir Crit Care Med 2003; 168: 916-917.
31. Oudijk EJ, Nijhuis EH, Zwank MD, et al: Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005; 60: 538-544.
32. Agustí AG, Noguera A, Sauleda J, et al: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
33. Seemungal TA, Donaldson GC, Bhowmik A, et al: Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613.